Annual CFI
$11.88 M
+$4.95 M+71.47%
December 31, 2023
Summary
- As of February 8, 2025, AVTE annual cash flow from investing activities is $11.88 million, with the most recent change of +$4.95 million (+71.47%) on December 31, 2023.
- During the last 3 years, AVTE annual CFI has risen by +$11.88 million (+100.00%).
- AVTE annual CFI is now at all-time high.
Performance
AVTE Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFI
$16.07 M
-$1.93 M-10.74%
September 30, 2024
Summary
- As of February 8, 2025, AVTE quarterly cash flow from investing activities is $16.07 million, with the most recent change of -$1.93 million (-10.74%) on September 30, 2024.
- Over the past year, AVTE quarterly CFI has increased by +$10.42 million (+184.47%).
- AVTE quarterly CFI is now -10.74% below its all-time high of $18.00 million, reached on June 30, 2024.
Performance
AVTE Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFI
$48.55 M
+$29.20 M+150.88%
September 30, 2024
Summary
- As of February 8, 2025, AVTE TTM cash flow from investing activities is $48.55 million, with the most recent change of +$29.20 million (+150.88%) on September 30, 2024.
- Over the past year, AVTE TTM CFI has increased by +$36.67 million (+308.79%).
- AVTE TTM CFI is now at all-time high.
Performance
AVTE TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Investing Formula
CFI = Cash Inflows from Investments − Cash Outflows for Investments
AVTE Cash From Investing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +71.5% | +184.5% | +308.8% |
| 3 y3 years | +100.0% | +184.5% | +308.8% |
| 5 y5 years | - | +184.5% | +308.8% |
AVTE Cash From Investing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +110.5% | -10.7% | +114.2% | at high | +136.3% |
| 5 y | 5-year | at high | +110.5% | -10.7% | +114.2% | at high | +136.3% |
| alltime | all time | at high | +110.5% | -10.7% | +114.2% | at high | +136.3% |
Aerovate Therapeutics Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $16.07 M(-10.7%) | $48.55 M(+150.9%) |
| Jun 2024 | - | $18.00 M(+103.8%) | $19.35 M(+262.8%) |
| Mar 2024 | - | $8.83 M(+56.4%) | $5.33 M(-55.1%) |
| Dec 2023 | $11.88 M(+71.5%) | $5.65 M(-143.0%) | $11.88 M(-42.7%) |
| Sep 2023 | - | -$13.13 M(-429.7%) | $20.71 M(-46.2%) |
| Jun 2023 | - | $3.98 M(-74.1%) | $38.49 M(-9.9%) |
| Mar 2023 | - | $15.38 M(+6.1%) | $42.70 M(+516.5%) |
| Dec 2022 | $6.93 M | $14.49 M(+211.9%) | $6.93 M(-105.7%) |
| Sep 2022 | - | $4.64 M(-43.3%) | -$120.90 M(-3.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2022 | - | $8.19 M(-140.2%) | -$125.60 M(-6.1%) |
| Mar 2022 | - | -$20.40 M(-82.0%) | -$133.79 M(+17.9%) |
| Dec 2021 | -$113.43 M(<-9900.0%) | -$113.34 M(>+9900.0%) | -$113.43 M(>+9900.0%) |
| Sep 2021 | - | -$56.00 K(<-9900.0%) | -$96.00 K(+140.0%) |
| Jun 2021 | - | $0.00(-100.0%) | -$40.00 K(0.0%) |
| Mar 2021 | - | -$40.00 K(<-9900.0%) | -$40.00 K(<-9900.0%) |
| Dec 2020 | $0.00 | $0.00(0.0%) | $0.00(0.0%) |
| Sep 2020 | - | $0.00(0.0%) | $0.00(0.0%) |
| Jun 2020 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2020 | - | $0.00 | $0.00 |
FAQ
- What is Aerovate Therapeutics annual cash flow from investing activities?
- What is the all time high annual CFI for Aerovate Therapeutics?
- What is Aerovate Therapeutics annual CFI year-on-year change?
- What is Aerovate Therapeutics quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Aerovate Therapeutics?
- What is Aerovate Therapeutics quarterly CFI year-on-year change?
- What is Aerovate Therapeutics TTM cash flow from investing activities?
- What is the all time high TTM CFI for Aerovate Therapeutics?
- What is Aerovate Therapeutics TTM CFI year-on-year change?
What is Aerovate Therapeutics annual cash flow from investing activities?
The current annual CFI of AVTE is $11.88 M
What is the all time high annual CFI for Aerovate Therapeutics?
Aerovate Therapeutics all-time high annual cash flow from investing activities is $11.88 M
What is Aerovate Therapeutics annual CFI year-on-year change?
Over the past year, AVTE annual cash flow from investing activities has changed by +$4.95 M (+71.47%)
What is Aerovate Therapeutics quarterly cash flow from investing activities?
The current quarterly CFI of AVTE is $16.07 M
What is the all time high quarterly CFI for Aerovate Therapeutics?
Aerovate Therapeutics all-time high quarterly cash flow from investing activities is $18.00 M
What is Aerovate Therapeutics quarterly CFI year-on-year change?
Over the past year, AVTE quarterly cash flow from investing activities has changed by +$10.42 M (+184.47%)
What is Aerovate Therapeutics TTM cash flow from investing activities?
The current TTM CFI of AVTE is $48.55 M
What is the all time high TTM CFI for Aerovate Therapeutics?
Aerovate Therapeutics all-time high TTM cash flow from investing activities is $48.55 M
What is Aerovate Therapeutics TTM CFI year-on-year change?
Over the past year, AVTE TTM cash flow from investing activities has changed by +$36.67 M (+308.79%)